Drug Information

Drug General Information
Drug ID
D03RYI
Former ID
DNCL002320
Drug Name
LY2606368 MsOH H2O
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [551090]
Company
Eli Lilly
Target and Pathway
Target(s) Serine/threonine-protein kinase Chk1 Target Info Modulator [543531]
KEGG Pathway Cell cycle
p53 signaling pathway
HTLV-I infection
Viral carcinogenesis
Pathway Interaction Database Fanconi anemia pathway
p73 transcription factor network
ATR signaling pathway
Circadian rhythm pathway
p53 pathway
Reactome Activation of ATR in response to replication stress
Processing of DNA double-strand break ends
Presynaptic phase of homologous DNA pairing and strand exchange
G2/M DNA damage checkpoint
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
WikiPathways DNA Damage Response
Signaling by SCF-KIT
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 551090Clinical pipeline report, company report or official report of Eli Lilly.
Ref 543531(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.